TALEN

TALEN1-nr5a2

ID

ZDB-TALEN-161128-1

Name

TALEN1-nr5a2

Previous Names

None

Target

nr5a2 (1)

Target Sequence 1

5' - CCTACGACGAAGACTTGGAT - 3'

Target Sequence 2

5' - ATCCGGACACCTTGTCT - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
oz3	nr5a2

Expression

Gene expression in Wild Types + TALEN1-nr5a2

No data available

Phenotype

Phenotype resulting from TALEN1-nr5a2

No data available

Phenotype of all Fish created by or utilizing TALEN1-nr5a2

Phenotype	Fish	Conditions	Figures
acinar cell prss1 expression absent, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. S1 from Nissim et al., 2016
digestive tract morphogenesis decreased process quality, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. 4 from Nissim et al., 2016
liver prox1a expression decreased distribution, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. 4 from Nissim et al., 2016
pancreatic bud foxa3 expression decreased distribution, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. 4 from Nissim et al., 2016
pancreas development decreased process quality, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. 4 from Nissim et al., 2016
exocrine pancreas decreased size, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. 2 from Nissim et al., 2016
exocrine pancreas prss1 expression decreased distribution, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. 2 from Nissim et al., 2016
pancreatic bud hhex expression decreased distribution, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. 4 from Nissim et al., 2016
pancreatic bud prox1a expression decreased distribution, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. 4 from Nissim et al., 2016
liver hhex expression decreased distribution, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. 4 from Nissim et al., 2016
liver foxa3 expression decreased distribution, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. 4 from Nissim et al., 2016
pancreatic bud decreased size, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. 4 from Nissim et al., 2016
liver fabp10a expression decreased distribution, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. 2 from Nissim et al., 2016
liver development decreased process quality, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. 4 from Nissim et al., 2016
liver hnf4a expression decreased distribution, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. 4 from Nissim et al., 2016
liver decreased size, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. 2 , Fig. 4 from Nissim et al., 2016
exocrine pancreas cpa5 expression absent, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. S1 from Nissim et al., 2016
pancreas morphogenesis process quality, abnormal	nr5a2^oz3/oz3	standard conditions	Fig. 4 from Nissim et al., 2016
liver prox1a expression decreased distribution, abnormal	nr5a2^oz3/+	standard conditions	Fig. 4 from Nissim et al., 2016
pancreatic bud foxa3 expression decreased distribution, abnormal	nr5a2^oz3/+	standard conditions	Fig. 4 from Nissim et al., 2016
digestive tract morphogenesis decreased process quality, abnormal	nr5a2^oz3/+	standard conditions	Fig. 4 from Nissim et al., 2016
pancreas development decreased process quality, abnormal	nr5a2^oz3/+	standard conditions	Fig. 4 from Nissim et al., 2016
exocrine pancreas decreased size, abnormal	nr5a2^oz3/+	standard conditions	Fig. 2 from Nissim et al., 2016
pancreatic bud hhex expression decreased distribution, abnormal	nr5a2^oz3/+	standard conditions	Fig. 4 from Nissim et al., 2016
exocrine pancreas prss1 expression decreased distribution, abnormal	nr5a2^oz3/+	standard conditions	Fig. 2 from Nissim et al., 2016
exocrine pancreas prss1 expression decreased distribution, abnormal	nr5a2^oz3/+	chemical treatment: 1-(3'-{1-[2-(morpholin-4-yl)ethyl]pyrazol-3-yl}[1,1'-biphenyl]-3-yl)ethan-1-one	Fig. 5 from Nissim et al., 2016
liver hhex expression decreased distribution, abnormal	nr5a2^oz3/+	standard conditions	Fig. 4 from Nissim et al., 2016
pancreatic bud prox1a expression decreased distribution, abnormal	nr5a2^oz3/+	standard conditions	Fig. 4 from Nissim et al., 2016
liver foxa3 expression decreased distribution, abnormal	nr5a2^oz3/+	standard conditions	Fig. 4 from Nissim et al., 2016
pancreatic bud decreased size, abnormal	nr5a2^oz3/+	standard conditions	Fig. 4 from Nissim et al., 2016
liver fabp10a expression decreased distribution, abnormal	nr5a2^oz3/+	standard conditions	Fig. 2 from Nissim et al., 2016
liver development decreased process quality, abnormal	nr5a2^oz3/+	standard conditions	Fig. 4 from Nissim et al., 2016
exocrine pancreas decreased size, abnormal	nr5a2^oz3/+	chemical treatment: 1-(3'-{1-[2-(morpholin-4-yl)ethyl]pyrazol-3-yl}[1,1'-biphenyl]-3-yl)ethan-1-one	Fig. 5 from Nissim et al., 2016
liver decreased size, abnormal	nr5a2^oz3/+	standard conditions	Fig. 2 , Fig. 4 from Nissim et al., 2016
pancreas morphogenesis process quality, abnormal	nr5a2^oz3/+	standard conditions	Fig. 4 from Nissim et al., 2016

Citations